ESR1 and breast carcinoma: Consistently, others have recently proposed that CSCs undergo dormancy to escape from anti-estrogen treatment and that targeting the ALDH+ IL-1 receptor+ cell population could be useful to prevent treatment resistance in ER+ breast cancer [59].